The NordICC trial was a randomized, pragmatic study that enrolled 84,585 adults aged 55 to 64 years old from Poland, Norway, and Sweden.
[T]he NordICC trial … fills an important knowledge gap and provides new insight into the real-world population-wide benefit of colonoscopy for colorectal cancer screening.
Preventing Colorectal Cancer
It is important to highlight an advantage of colorectal cancer screening that distinguishes it from all other cancer screening modalities.Colorectal cancer screening with endoscopy is unique in that it aims to, in part, prevent disease by identifying and removing premalignant lesions.
Women are more likely to feel their symptoms are not being taken seriously by doctors. Why?
“Medical gaslighting” is a controversial term that has emerged to describe a phenomenon some people – women in particular – may recognise. It refers to a patient’s feeling that their symptoms are not taken seriously, or are being misdiagnosed by healthcare professionals.
Now researchers are interested in understanding why this is, and whether gender stereotyping might play a role. Are doctors more likely to attribute pain or exhaustion in women to non-physical causes such as stress?
Conclusion:Adopting a co-design process helped ensure that the decision aid components were relevant and accessible to the target population. The template could have widespread application through being adapted for different genetic predispositions. The exact content should be co-designed with people from diverse backgrounds with lived experience of the specific predisposition to ensure it is as useful, engaging and relevant as possible
The recommended lifestyle has beneficial associations with most cancers. In terms of absolute risk, the protective association is greater for higher genetic risk groups for some cancers. These findings have important implications for persons most genetically predisposed to those cancers and for targeted strategies for cancer prevention.
In summary, LS care has come a long way over the last twenty years. We now understand the individual cancer risk to inform consent, tests to accurately diagnoses LS and ways by which we can reduce cancer risk.
However, more needs to be done to find those who are undiagnosed, develop less invasive cancer surveillance methods and develop new vaccinations and treatments.
Lynch syndrome increases the risk of many different types of cancer, including ovarian cancer. The exact level of risk depends on which gene contains the mutation.
Overall, ovarian cancer is rare. The American Cancer SocietyTrusted Source estimates that 1 in 78 (1.2%) of people with ovaries will develop ovarian cancer during their lifetime. Additionally, more than half of people receive a diagnosis at age 63 or older.
In contrast, people with Lynch syndrome have a 3% to 17% lifetime risk of developing ovarian cancer. They also often develop cancer at a younger age than people without Lynch syndrome.